TELEPHONE: +1 (503) 894-6022 E-MAIL: sales@researchbeam.com
The report provides comprehensive information on the therapeutics under development for Lung Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplantation and features dormant and discontinued projects. Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Read More At: http://www.researchbeam.com/lung-transplantation-pipeline-reviewh1-2016-market
Scope
• The report provides a snapshot of the global therapeutic landscape of Lung Transplantation • The report reviews key players involved Lung Transplantation therapeutics and enlists all their major and minor projects • The report assesses Lung Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type • The report summarizes all the dormant and discontinued pipeline projects
Reasons to buy
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies • Identify potential new clients or partners in the target demographic • Devise corrective measures for pipeline projects by understanding Lung Transplantation pipeline depth and focus of Indication therapeutics • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
List of Tables Number of Products under Development for Lung Transplantation, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Lung Transplantation - Pipeline by Kamada Ltd., H1 2016 13 Lung Transplantation - Pipeline by Proteo, Inc., H1 2016 14 Lung Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Lung Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 42 Lung Transplantation - Dormant Projects, H1 2016 49 Enquire More At: http://www.researchbeam.com/lung-transplantation-pipeline-reviewh1-2016-market/enquire-about-report
Visit us at http://www.researchbeam.com/lung-transplantation-pipelinereview-h1-2016-market
Stay With Us:
TELEPHONE: +1 (800) 910-6452 DIRECT: +1 (503) 894-6022 E-MAIL: sales@researchbeam.com
5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States